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Abstract
Resveratrol is a naturally occurring polyphenol that provides a number of anti-aging health
benefits including improved metabolism, cardioprotection, and cancer prevention. Much of
the work on resveratrol and cancer comes from in vitro studies looking at resveratrol actions
on cancer cells and pathways. There are, however, comparatively fewer studies that have
investigated resveratrol treatment and cancer outcomes in vivo, perhaps limited by its poor
bioavailability when taken orally. Although research in cell culture has shown promising and
positive effects of resveratrol, evidence from rodents and humans is inconsistent. This review
highlights the in vivo effects of resveratrol treatment on breast, colorectal, liver, pancreatic,
and prostate cancers. Resveratrol supplementation in animal models of cancer has shown
positive, neutral as well as negative outcomes depending on resveratrol route of
administration, dose, tumor model, species, and other factors. Within a specific cancer type,
there is variability between studies with respect to strain, age, and sex of animal used, timing
and method of resveratrol supplementation, and dose of resveratrol used to study cancer
endpoints. Together, the data suggest that many factors need to be considered before
resveratrol can be used for human cancer prevention or therapy.
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Introduction
Resveratrol (trans-3,5,4 0-trihydroxystilbene) is a phytoa-
lexin found in many plant species, including those often
consumed by humans such as grapes, peanuts, and berries;
it is produced in plants in response to mechanical injury,
fungal infection, and u.v. radiation (Langcake & Pryce
1976). The highest naturally occurring levels of resveratrol
are found in Polygonum cuspidatum ( Japanese knotweed),
a plant which has been used for hundreds of years in
traditional Asian medicine to treat inflammation and
other ailments (Vastano et al. 2000, Burns et al. 2002).
Concentrations of resveratrol vary markedly between
plant species. In blueberries, for example, resveratrol
concentrations approximate only 32 ng/g, compared
with levels up to 1920 and 3540 ng/g in peanuts and
grapes respectively (other beneficial compounds are also
present in varying quantities; Sanders et al. 2000, Burns
et al. 2002, Lyons et al. 2003). Resveratrol is not only found
in these plants, but also in processed products such
as wine. In fact, many attribute the ‘French Paradox’ in
which moderate wine consumption is associated with
decreased risk of coronary heart disease (Renaud & de
Lorgeril 1992), to be the result of red wine’s relatively high
resveratrol concentration (0.1–14.3 mg/l) (Goldberg et al.
1995, Kiraly-Veghely et al. 1998, Kopp 1998, Pervaiz 2003).
Nonetheless, wine’s resveratrol content is typically much
lower than what has been shown experimentally to have
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health benefits, but recent work has suggested that lower
levels of resveratrol can also provide health improvements
(Tome-Carneiro et al. 2012). For a review and discussion
of the clinical literature along with the limitations of
preclinical and in vitro resveratrol studies, see Tome-
Carneiro et al. (2013). Further, Baur & Sinclair (2006)
provide a thorough review of the in vivo effects of
resveratrol on many disease states.
Because resveratrol is a naturally occurring
compound, it has been highly studied for the prevention
and treatment of many diseases including cancer. After
Jang et al. (1997) found that topical application of
resveratrol protected mice from tumorigenesis in a skin
cancer model in 1997, a wealth of publications followed.
In animals, supplemental doses of resveratrol protect
against many of the deleterious effects of high-fat diets
and provide additional health benefits (Hung et al. 2000,
Bradamante et al. 2004, Baur et al. 2006, Lagouge et al.
2006, Pearson et al. 2008, Ramadori et al. 2009, Kang et al.
2010). Numerous in vitro studies have shown that
resveratrol has multiple anti-cancer effects, protecting
against both tumor initiation and cancer progression
pathways. For example, resveratrol can promote cell
cycle arrest leading to apoptosis of tumor cells, prevent
tumor-derived nitric oxide synthase expression to block
tumor growth and migration, as well as act as an
antioxidant to prevent DNA damage that can lead to
tumor formation (Clement et al. 1998, Tsai et al. 1999,
Nakagawa et al. 2001, Murakami et al. 2003, Garvin et al.
2006, Kalra et al. 2008). In addition, resveratrol inhibits
cyclooxygenase (COX) activity, which is known to play a
role in tumorigenesis by converting arachidonic acid to
prostaglandins, inflammatory compounds that promote
tumor cell proliferation (Subbaramaiah et al. 1998, Jang &
Pezzuto 1999, MacCarrone et al. 1999). Resveratrol has
also been shown in multiple studies to decrease DNA
binding activity of nuclear factor kB (NF-kB), which is a
transcription factor that is known to be upregulated in
cancers and can drive the transcription of genes that
promote tumor growth (Holmes-McNary & Baldwin 2000,
Benitez et al. 2009, Csaki et al. 2009, Roy et al. 2009).
Resveratrol appears to have many anti-tumor effects
on different cancer cells in vitro and these effects and
pathways have been extensively reviewed (Bhat & Pezzuto
2002, Dong 2003, Le Corre et al. 2005, Kundu & Surh 2008,
Shukla & Singh 2011). Regarding in vivo evidence, Jang
et al. (1997) were the first to show that resveratrol may
act as a chemopreventative agent when they found that
topical application of the compound was able to inhibit
tumor formation in the two-stage skin cancer model in
mice. Later studies found that in mouse models of skin
tumorigenesis, topical resveratrol prevented tumor forma-
tion by promoting apoptosis, regulating the cell cycle, and
inhibiting COX activity and prostaglandin production
(Afaq et al. 2003, Reagan-Shaw et al. 2004, Kalra et al.
2008). The in vivo use and efficacy of resveratrol for other
types of cancer that require oral consumption or injection
of resveratrol, however, have been less straight forward.
This is due, in part, to the poor bioavailability of trans-
resveratrol. Wenzel & Somoza (2005) provide a critical and
detailed review of the bioavailability and metabolism of
resveratrol. In rodents and humans, when resveratrol is
consumed orally, 70–80% is quickly absorbed via passive
diffusion in the intestines (Andlauer et al. 2000, Soleas
et al. 2001, Kaldas et al. 2003, Walle et al. 2004). After
absorption, resveratrol is conjugated into glucuronides
and sulfates, so that circulating levels of trans-resveratrol
peak 30–60 min post oral administration (Andlauer et al.
2000, De Santi et al. 2000, Soleas et al. 2001, Yu et al. 2002).
In humans, circulating levels of unmodified trans-
resveratrol are onlyw2% of the peak serum concentration
of total free resveratrol and conjugates after a single dose
of 25 mg/70 kg body weight (BW; Goldberg et al. 2003).
Another report shows that at least 70% of resveratrol is
absorbed after a single 25 mg dose, and there is a peak
serum concentration of 2 mM (w490 ng/ml) for resveratrol
and all of its metabolites (Walle et al. 2004). After multiple
oral doses (5 g daily for 29 days), plasma concentrations
of trans-resveratrol have been reported to be as high as
w4 mM (4.29 nmol/ml); however, it should be noted that
resveratrol at this high dose was also associated with
gastrointestinal side effects (Brown et al. 2010). Interest-
ingly, in human colon tissue, levels of resveratrol and its
metabolite resveratrol-3-O-glucuronide have been found
at high concentrations (674 and 86 nmol/g respectively)
when 0.5–1.0 g of resveratrol was taken orally once per day
(Patel et al. 2010). In this study, resveratrol supple-
mentation was shown to decrease cellular proliferation
by 5% in colorectal cancer tissue, as assessed by Ki67
staining (Patel et al. 2010). Since there is such rapid
conjugation and low bioavailability of resveratrol, the
in vivo use of resveratrol for cancer prevention and
treatment is uncertain. Therefore, it is the intention of
this review to highlight findings from in vivo studies.
First, this review will briefly discuss the limited clinical
evidence currently available on resveratrol and cancer
treatment and prevention. Then, given the vast amount of
research done with resveratrol and cancer (a PubMed
search of ‘resveratrol and cancer’ yielded more than 1800
hits) and the more recent interest in obesity as a risk factor
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for cancer, this review will focus primarily on the in vivo
studies involving resveratrol and several obesity-related
cancers; specifically breast, colorectal, hepatic, pancreatic,
and prostate cancers. Tables 1, 2, 3, 4 and 5 summarize
the methods and outcomes of in vivo experiments that
have tumor formation as an endpoint measurement rather
than those studies that investigate the mechanisms,
biomarkers, or pathway changes.
Clinical studies
Clinical evidence for resveratrol as an effective supplement
for cancer prevention and treatment is scarce. In 2009,
the first phase I clinical trial looking at resveratrol
treatment in patients diagnosed with cancer was published
(Nguyen et al. 2009). Patients with colorectal cancer (nZ8)
had normal and cancerous intestinal mucosal samples
biopsied at the time of diagnosis and 14 days after daily
resveratrol (20 or 80 mg/day; nZ2 and 1 respectively) or
grape powder (80 or 120 g/day; nZ3 and 2 respectively)
oral supplementation at the time of colon cancer resection
surgery. The Wnt signaling pathway, known to be
involved in the formation of colon cancer, was evaluated
in normal and cancerous mucosa, before and after
resveratrol or grape powder supplementation. Target
genes in the Wnt pathway were significantly higher in
cancerous compared with normal mucosa. Resveratrol and
grape powder administration had no effect on cancerous
mucosa Wnt signaling, but their supplementation resulted
in decreased Wnt target gene expression in normal
mucosa (effects of all treatment groups combined). The
most significant effects were observed with the low-dose
Table 1 Breast cancer
References Strain/species Sex Agea Tumor model
Resveratrol dose
and administration
Effect on
tumorigenesisb
Bhat et al. (2001) Sprague–Dawley
rats
F 42 days NMU I.g.; 10 or 100 mg/kg BW;
5!/week; 7 days before
initiation – 120 days after
Positivec
Banerjee et al.
(2002)
Sprague–Dawley
rats
F 45 days DMBA 0.001% in diet; 100 mg/rat
daily; 7 days before
initiation – 120 days after
initiation
Positive
Bove et al. (2002) BALB/c mice F 17 weeks 4T1 cells I.p.; 1, 3, or 5 mg/kg BW; daily;
23 days started at injection
Unchanged
Sato et al. (2003) Sprague–Dawley
rats
F 15 days NMU S.c.; 10 or 100 mg/kg BW; daily
for 5 days; from 30 to 34 days
before initiation
Negativec
Provinciali et al.
(2005)
HER2/neu mice F 20 weeks Spontaneous
tumors
0.0001% in drinking water;
4 mg/mouse daily; for
11 weeks
Positive
Garvin et al. (2006) Nude mice F 6–8 weeks MDA-MB-231
(ERa(K), ERb(C))
cells
I.p.; 25 mg/kg BW; daily; for
3 weeks after tumor size
reached 40 mm3
Positive
Whitsett et al.
(2006)
Sprague–Dawley
rats
F 0 days DMBA 0.1% in diet; daily; 50 days
before initiation – 18 weeks
after initiation
Positive
Chatterjee et al.
(2011)
Sprague–Dawley
rats
F 5 weeks DMBA 0.001% in diet; 100 mg/rat
daily; 2 weeks before
initiation – 24 weeks after
initiation
Positive
Castillo-Pichardo
et al. (2013)
SCID mice F 5–6 weeks MDA-MB-231
(ERa(K), ERb(C))
cells
Gavage; 0.5, 5, or 50 mg/kg
BW; 5!/week; 7 days after
injection for 108 days
Negative
Castillo-Pichardo
et al. (2013)
Nude mice F 5–6 weeks MDA-MB-435
(ER(K)) cells
Gavage; 0.5, 5, or 50 mg/kg
BW; 5!/week; 7 days after
injection for 44 days
Negative
BW, body weight; DMBA, 7,12-dimethylbenz(a)anthracene; ER, estrogen receptor; F, female; i.g., intragastric intubation; NMU, N-nitroso-N-methylurea;
SCID, severe combined immunodeficiency.
aAge in table indicates age of animal when study was started; either when tumors were initiated or when resveratrol was administered, depending on study
design.
b Review authors’ interpretation of paper results with a focus on tumor outcomes.
cLower dose did not significantly affect outcomes.
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grape powder. This led the authors to conclude that
resveratrol in combination with other compounds found
in grapes could possibly be used to decrease the risk of
colon cancer development by decreasing Wnt pathway
signaling, but might not be as effective against established
colon cancer. The second clinical study observed the
effects of resveratrol treatment in colorectal cancer
patients with hepatic metastasis (nZ9). Resveratrol
supplementation (5 g daily of microionized resveratrol
SRT501 for 10–21 days; nZ6) increased the expression of
cleaved caspase-3 in cancerous hepatic tissue, indicating
increased apoptosis of cancerous cells compared with
those of placebo-treated subjects (nZ3) (Howells et al.
2011). It is important to caution that patient sample size in
these clinical trials was small (only eight and nine cancer
patients were enrolled in the studies respectively), high-
lighting the fact that so far, there is very little human data
for the efficacy of resveratrol in cancer treatment.
A few other clinical studies have focused on resveratrol
supplementation and predictors for cancer prevention and
cancer risk factors in healthy subjects. Given that increases
in insulin-like growth factor 1 (IGF1) and decreases in IGF-
binding protein 3 (IGFBP3) are associated with tumor
formation and metastasis, one study looked at the effects
of resveratrol supplementation (0.5, 1.0, 2.5, and 5 g/day
for 29 days; nZ10–12/dose) on circulating levels of these
proteins (Brown et al. 2010). After 29 days of supple-
mentation, the authors found that resveratrol treatment at
2.5 g/day significantly reduced IGF1 and IGFBP3 levels in
plasma, which would support the use of resveratrol as a
chemopreventative agent in humans. The 1.0 g/day dose
also caused a significant decrease in plasma IGFBP3
compared with pretreatment baseline levels. The two
higher doses did cause some short-term mild to moderate
gastrointestinal symptoms in multiple subjects (Brown
et al. 2010). In another trial, healthy subjects were given
1 g of resveratrol for 4 weeks and lymphocyte levels or
surrogate markers of activity levels of enzymes involved
in carcinogenesis and drug metabolism were measured
(Chow et al. 2010). Resveratrol supplementation increased
the protein or activity levels of a variety of carcinogen-
detoxifying enzymes, such as glutathione S-transferase
and glucuronosyltransferase, but a significant increase was
only reached where enzyme levels were low at baseline.
Chow et al. (2010) noted the important caveat that
although pharmacologic resveratrol supplementation
seems well tolerated and may exert a cancer-protective
effect through enhanced detoxification of carcinogens,
Table 2 Colorectal cancer
References Strain/species Sex Agea Tumor model
Resveratrol dose
and administration
Effect on
tumorigenesisb
Tessitore et al.
(2000)
F344 rats M 8 weeks AOM In drinking water; 200 mg/kg BW
daily; 10 days before initiation,
continued for 100 days
Positive
Schneider et al.
(2001)
APCMin/C mice M 5 weeks Spontaneous
tumors
0.01% in drinking water; between
0.3 and 0.4 mg/mouse daily for
7 weeks
Positive
Ziegler et al.
(2004)
APCMin/C mice M 43 days Spontaneous
tumors
In diet; 4, 20, or 90 mg/kg BW daily
for 7 weeks
Unchanged
Sale et al.
(2005)
APCMin/C mice M 4 weeks Spontaneous
tumors
0.05 or 0.2% in diet; 60 or 240 mg/kg
BW daily for 10–14 weeks
Positivec
Sengottuvelan &
Nalini (2006)
Wistar rats M Adult DMH I.g.; 8 mg/kg BW; daily; 2 weeks
before first DMH – final DMHd
Positive
Sengottuvelan &
Nalini (2006)
Wistar rats M Adult DMH I.g.; 8 mg/kg BW; daily; 2 days after
final DMH – 15 weeks after final
DMHd
Positive
Sengottuvelan &
Nalini (2006)
Wistar rats M Adult DMH I.g.; 8 mg/kg BW; daily; on day of
first DMH – 30 weeks afterd
Positive
Majumdar et al.
(2009)
SCID mice F 7 weeks HCT-116 (wt) cells Gavage; 150 mg/kg BW; daily;
15 days after injection for 3 weeks
Positive
Alfaras et al.
(2010)
Sprague–
Dawley rats
M 8 weeks DMH Gavage; 60 mg/kg BW; daily; 7 days
before initiation for 49 days
Positive
AOM, azoxymethane; BW, body weight; DMH, 1,2-dimethylhydrazine; i.g., intragastric intubation; M, male; SCID, severe combined immunodeficiency.
aAge in table indicates age of animal when study was started; either when tumors were initiated or when resveratrol was administered, depending on study
design.
bReview authors’ interpretation of paper results with a focus on tumor outcomes.
cUnchanged for lower dose.
dDMH was given once weekly for 15 weeks, and then the rats were killed 15 weeks after the last DMH injection (30 weeks after initial DMH exposure).
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it might also have the potential to alter the metabolism of
a variety of medications through the inhibition of cyto-
chrome P450 activity. Therefore resveratrol’s safety and
benefit must be further delineated, particularly in the
context of co-administering it with pharmaceutical agents.
From this limited clinical trial data, it is apparent that
much more human research is needed before resveratrol
can be considered as a viable option for cancer prevention
or therapy. There are several other completed clinical trials
looking at resveratrol and cancer that have yet to publish
results and one on-going clinical trial (clinicaltrials.gov).
All of these trials are focusing either on patients with
colorectal cancer or are assessing cancer prevention
capabilities of resveratrol in healthy patients. Thus far,
its most promising use seems to be in cancer prevention
instead of treatment. It is important to note that there is
some evidence that resveratrol may have adverse effects in
certain cancer patients. In a phase II clinical trial involving
relapsed or refractory multiple myeloma patients, resver-
atrol at a dose of 5 g/day caused adverse events (including
nausea, diarrhea, fatigue, and renal toxicity), which may
have contributed to the death of one patient and caused
the investigators to prematurely end the study (Popat et al.
2013). The authors note that this high dose has been
shown to be safe in other clinical trials in healthy patients.
This highlights the need for more research into the efficacy
and safety of resveratrol in in vivo cancer models. Later
we will discuss much of the work that has been completed
with resveratrol use in animal models of breast, colorectal,
hepatic, pancreatic, and prostate cancers.
Animal studies
Breast cancer
Breast cancer accounts for one in three diagnosed cancers
in women in the USA (DeSantis et al. 2011a,b). Current
treatment options for breast cancer include chemother-
apy, radiation, or surgery to remove tumors and breast
tissue. Hormone therapy is also available, especially for
post-menopausal women. Resveratrol is considered a
phytoestrogen that seems to have both agonistic and
antagonistic effects on estrogen (Bowers et al. 2000, Bhat
et al. 2001). Given this, it makes sense that research
conducted on resveratrol and estrogen-related cancers
have found diverse results. In several animal models,
resveratrol supplementation was shown to decrease the
incidence of mammary tumor formation. In 45-day old
female Sprague–Dawley rats, resveratrol supplementation
in the diet (0.001%; daily intake calculated to be
100 mg/rat) started 7 days before tumor initiation and
continued for 120 days after initiation was found to
Table 3 Liver cancer
References Strain/species Sex Agea Tumor model
Resveratrol dose and
administration
Effect on
tumorigenesisb
Carbo et al.
(1999)
Wistar rats M Adultc AH-130 cells I.p.; 1 mg/kg BW; daily; 7 days
starting at injection
Positive
Bishayee & Dhir
(2009)
Sprague–
Dawley rats
F 31–37 daysd DENACPB 0.06, 0.12, or 0.36% in diet; 50, 100,
or 300 mg/kg BW daily; 4 weeks
before initiation – 16 weeks after
Positivee
Luther et al.
(2011)
Sprague–
Dawley rats
F 31–37 days DENACPB 0.06, 0.12, or 0.36% in diet; 50, 100,
or 300 mg/kg BW daily; 4 weeks
before initiation – 14 weeks after
Positive
Rajasekaran et al.
(2011)
Wistar rats M 6–8 weeks DENACPB Gavage; 20 mg/kg BW; daily; on day
of initiation – 15 days after
Positive
Rajasekaran et al.
(2011)
Wistar rats M 6–8 weeks DENACPB Gavage; 20 mg/kg BW; daily; for
15 days from 17 to 18 weeks after
initiation
Positive
Salado et al.
(2011)
C57BL/6J mice M 6–8 weeks B16M cells
metastasis
I.g.; 1 mg/kg BW; daily; day of
injection – 12 days after
Positive
Lin et al. (2012) HBx mice M 12 months Spontaneous
tumors
0.024% in diet; 30 mg/kg BW daily;
for 4 months
Positive
BW, body weight; DENA, diethylnitrosamine; F, female; HBx, hepatitis B virus X protein; i.g., intragastric intubation; M, male; PB, phenobarbital.
aAge in table indicates age of animal when study was started; either when tumors were initiated or when resveratrol was administered, depending on study
design.
bReview authors’ interpretation of paper results with a focus on tumor outcomes.
cAge was not given but the rats were w100 g.
dAge was not given but the rats were the same weight (65–85 g) as the group’s next paper (Luther et al. 2011).
eUnchanged for lowest dose.
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increase time to first tumor formation and decrease tumor
incidence and multiplicity following 7,12-dimethylben-
z(a)anthracene (DMBA) administration (Banerjee et al.
2002). Analysis of the tumor tissue also showed that
resveratrol reduced DMBA-generated COX2 expression
and NF-kB binding to DNA. In a similar rat mammary
tumor model, supplementation of a higher dose of
resveratrol in the diet (0.1%), starting at birth and
continuing for 180 days, decreased tumor number per
rat and increased latency to tumor development after
tumor initiation at postnatal day 50 (Whitsett et al. 2006).
For resveratrol supplementation starting at birth, nursing
dams were fed the diets containing resveratrol and pups
were then weaned onto the same diet. Cellular prolifer-
ation and apoptosis in the mammary tumor tissue was also
measured. Proliferating cell percentage was reduced with
resveratrol treatment, while apoptotic-labeling index
(epithelial cells stained positive for apoptosis/total num-
ber of epithelial cells) was increased compared with
control diet-fed rats (Whitsett et al. 2006).
Using young, 5-week-old female Sprague–Dawley rats
and a DMBA carcinogenesis model, Chatterjee et al. (2011)
found that resveratrol supplementation in the diet
(0.001%; daily intake calculated to be 100 mg/rat)
decreased palpable mammary tumor incidence 11 weeks
after DMBA exposure. After 24 weeks of supplementation,
animals were killed and mammary tissue was analyzed
for DNA damage, 5-lipoxygenase (5-LOX), transforming
growth factor b1 (TGFb1), NF-kB, cell proliferation,
and apoptosis, all of which can be the indicators of
tumorigenesis. Resveratrol treatment positively impacted
all of these markers in the mammary tissue; it decreased
the appearance of single-strand DNA, indicating less DNA
damage; decreased 5-LOX expression and activity;
decreased TGFb1 and NF-kB expression; decreased cell
proliferation; and increased the number of apoptotic cells.
In a different model of rat mammary tumorigenesis using
N-nitroso-N-methylurea (NMU) to promote tumor forma-
tion in 49-day-old Sprague–Dawley females, resveratrol
was given by oral gavage (10 or 100 mg/kg BW) five times a
week for 1 week before NMU injection and continued for
120 days after. The higher dose of resveratrol resulted in a
significant delay in tumor formation and decrease in
tumor multiplicity, while the lower dose did not signi-
ficantly alter these parameters compared with control
(Bhat et al. 2001). In a model of spontaneous mammary
tumor formation, 20-week-old female FVB/N HER2/neu
transgenic mice treated with resveratrol in their drinking
water (0.0001%; daily intake calculated to be 4 mg/mouse)
for 11 weeks had a significant increase in latency to tumor
formation. Resveratrol treatment also decreased tumor
number and size per animal and reduced tumor metastasis
to the lungs (Provinciali et al. 2005). In a xenograft model
where athymic nude female mice from 6 to 8 weeks of age
were injected with MDA-MB-231 (estrogen receptor
(ER)a(K), ERb(C)) cells, Garvin et al. found that resvera-
trol (25 mg/kg BW; i.p. injection) given daily for 3 weeks
after tumors had already reached 40 mm3 caused a
significant reduction in tumor growth. Tumors in
vehicle-treated controls increased in size by four- to
Table 4 Pancreatic cancer
References Strain/species Sex Agea Tumor model
Resveratrol dose and
administration
Effect on
tumorigenesisb
Kuroiwa et al.
(2006)
Syrian hamsters M 6 weeks BOP 0.001% in diet; daily; 1 week before
initiation for 3 weeks
Unchanged
Kuroiwa et al.
(2006)
Syrian hamsters M 6 weeks BOP 0.001% in diet; daily; 1 week after initial
BOP injection for 14 weeks
Unchanged
Harikumar et al.
(2010)
Nude mice M 4 weeks MIA PaCa-2
cells
Gavage; 40 mg/kg BW; daily; 1 week
after injection for 4 weeks
Positive
Oi et al. (2010) Nude mice – 6–8 weeks MIA PaCa-2
cells
Gavage; 10 or 50 mg/kg BW;
5!/week; 2 weeks before injection –
tumors reaching 1 cm3 volume
Positivec
Roy et al. (2011) Nude mice – 4–6 weeks PANC-1 cells Gavage; 20, 40, or 60 mg/kg BW;
5!/week, 1 week after injection
for 6 weeks
Positive
Shankar et al.
(2011)
KrasG12D mice – 8 weeks Spontaneous
tumors
Gavage; 40 mg/kg BW; 5!/week;
forw10 months
Positive
BOP, N-nitrosobis(2-oxopropyl)amine); BW, body weight; M, male.
aAge in table indicates age of animal when study was started; either when tumors were initiated or when resveratrol was administered, depending on study
design.
bReview authors’ interpretation of paper results with a focus on tumor outcomes.
cThe protection was dose dependent, but the lower dose was not significantly improved compared to vehicle control.
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fivefold over the next 3 weeks, while tumors in resveratrol-
treated mice did not increase in size. Furthermore,
apoptosis was increased and angiogenesis was decreased
in the tumor cells from resveratrol-compared with
vehicle-treated mice (Garvin et al. 2006). Taken together,
these animal models suggest that resveratrol could
potentially be used as a chemopreventative or cancer
treatment agent.
Other studies have not shown such promising results
for resveratrol as a breast cancer therapy. In 17-week-old
BALB/c female mice, 4T1 mammary carcinoma cells (an
ERa- and Erb-positive cell line) were injected and breast
tumor formation and metastasis to the lungs were
monitored (Bove et al. 2002). Mice that were treated with
resveratrol at 1, 3, or 5 mg/kg BW daily (i.p. injection) for
23 days following tumor cell injection showed no
differences in mammary tumor latency, mammary
tumor number, or tumor metastasis to the lungs compared
with vehicle-treated mice injected with the 4T1 cells
(Bove et al. 2002). Castillo-Pichardo et al. injected low
metastatic cells ERa(K), ERb(C) MDA-MB-231, or high
metastatic ER(K) MDA-MB-435 cancer cells into 5- to
6-week-old female mice with severe combined immuno-
deficiency (SCID) and athymic nude (nu/nu) respectively.
They then evaluated tumor formation and metastasis with
or without resveratrol supplementation (0.5, 5, or
50 mg/kg BW; oral gavage) starting 7 days after tumor
cell injection and continuing for 44 or 108 days (Castillo-
Pichardo et al. 2013). At all concentrations of dietary
supplementation and in both cell types, there was an
increase in mammary tumor formation and metastasis
compared with vehicle-treated mice. Because phytoestro-
gens such as resveratrol can affect development in
prepubertal animals, Sato et al. (2003) treated female
Sprague–Dawley rats daily with resveratrol on postnatal
days 15–19 (10 or 100 mg/kg BW; s.c. injection). On
postnatal day 49, rats were injected with NMU to promote
mammary tumor formation. Resveratrol at 100 mg/kg BW
given on postnatal days 15–19 had no effect on tumor
latency but increased the multiplicity of tumors and the
incidence of rats with tumors R1 cm. The lower dose did
not cause the same negative effects, but it was not
beneficial either (Sato et al. 2003). These studies suggest
that caution must be applied in adapting resveratrol for
human use and may indicate that resveratrol can promote
mammary tumor growth and formation depending on cell
type and other factors. A summary of these studies is
provided in Table 1.
Colorectal cancer
Colorectal cancer is one of the leading causes of cancer
deaths in the Western world (Siegel et al. 2012). Diet and
lifestyle have been shown to have a significant impact on
the development of colorectal cancers (Doll & Peto 1981,
Willett 1995), making resveratrol an interesting treatment
possibility for this cancer type. Furthermore, oral admin-
istration of resveratrol might be expected to have a
maximal impact on local intestinal processes before
metabolic inactivation by the liver. Several different
animal models have been used to evaluate the effect of
resveratrol treatment on colon tumor formation. Using
Table 5 Prostate cancer
References Strain/species Sex Agea Tumor model
Resveratrol dose
and administration
Effect on
tumorigenesisb
Harper et al.
(2007)
TRAMP mice M 5 weeks Spontaneous
tumors
0.0625% in diet; daily for 23 weeks Positive
Seeni et al. (2008) TRAP rats M 3 weeks Spontaneous
tumors
0.005, 0.01, or 0.02% in drinking water;
daily for 7 weeks
Positive
Seeni et al. (2008) Nude mice M 6 weeks PLS30 cells 0.01 or 0.02% daily in drinking water;
1 week after cell
injection – 6 weeks after
Unchanged
Wang et al.
(2008)
Nude mice M 5 weeks LNCaP cells 0.005 or 0.01% in diet; daily; 2 weeks
before cell injection – 7 weeks after
Unchangedc
Dias et al. (2013) Nude mice M 6–7 weeks LNCaP cells Gavage; 50 mg/kg BW; every other day;
2 weeks prior to cell injection –
5 weeks after
Positive
BW, body weight; M, male; TRAP, transgenic rats for adenocarcinoma of prostate; TRAMP, transgenic adenocarcinoma of mouse prostate.
aAge in table indicates age of animal when study was started; either when tumors were initiated or when resveratrol was administered, depending on study
design.
bReview authors’ interpretation of paper results with a focus on tumor outcomes.
cResveratrol delayed tumor growth at 3 weeks (both doses) and 4 weeks (higher dose only) post injection compared with mice on control diet, but there
were no differences in tumor size after 7 weeks at the end of the study.
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azoxymethane to induce colon tumorigenesis in 8-week-
old male Fisher 344 rats, Tessitore et al. (2000) found that
resveratrol supplementation in drinking water (daily
intake calculated to be 200 mg/kg BW) for 100 days
decreased the appearance of aberrant crypt foci (ACF)
precursors for colon cancer compared with rats receiving
control water. They also found that resveratrol treatment
reduced the appearance of large-sized ACF as well as
increased the expression of Bcl2-associated X (Bax), a pro-
apoptotic protein in precancerous cells. Other studies have
used 1,2-dimethylhydrazine (DMH) to promote colon
tumor formation in rats in order to study the chemopre-
ventative effects of resveratrol. Sengottuvelan & Nalini
exposed adult male Wistar rats to DMH once weekly for 15
weeks and then killed the rats 30 weeks after the initial
DMH injection. The rats were then treated daily with
vehicle or resveratrol (8 mg/kg BW; oral gavage): i) before
and during DMH initiation (2 weeks before and through-
out the 15 weeks DMH treatment), ii) after the final DMH
treatment (2 days after the last DMH injection to the end
of the study), and iii) from the initial DMH treatment until
the end of the experiment. They found that all three
resveratrol exposure protocols decreased tumor incidence
and the number of ACF compared with vehicle-treated
DMH rats (Sengottuvelan & Nalini 2006). This same group
also looked at the markers of inflammation, cell prolifer-
ation, and apoptosis in intestinal mucosa sampled from
rats injected with DMH, with or without a similar
resveratrol supplementation protocol. Resveratrol reduced
COX2 expression and activity, decreased ornithine dec-
arboxylase which is highly expressed in cells during cell
proliferation and tumor promotion, and increased
the presence of cleaved capsase-3, indicating cellular
apoptosis (Sengottuvelan et al. 2009). In 8-week-old
Sprague–Dawley male rats, treatment with resveratrol by
gavage over a 49-day period starting 7 days before tumor
initiation (60 mg/kg BW) reduced the number of intestinal
ACF as well as mucin-depleted foci (MDF) following DMH
injection (Alfaras et al. 2010). MDF reduction is important
because MDF foci are characterized by deregulated Wnt
signaling (Yang et al. 2008), which is considered to be a
major risk factor for colon cancer development (Moon
et al. 2004, Sancho et al. 2004).
Other studies used a mouse model of spontaneous
colon tumor formation. Adenomatous polyposis coli
(Apc)Min/C mice contain a germ line mutation in the
tumor suppressor gene adenomatous polyposis and are
predisposed to develop colon cancer (Wechter et al. 2000).
Since spontaneous tumors in these mice are sensitive to
COX inhibitors, resveratrol use to prevent tumor
formation was of interest in this model (Jacoby et al.
1996, 2000). In one study, when 5-week-old male
C57BL/6J-ApcMin/C mice were treated with resveratrol for
7 weeks (0.01% in drinking water; daily intake calculated
to be between 0.3 and 0.4 mg/mouse per day), resveratrol
supplementation resulted in a 70% reduction in small
intestinal tumors compared with vehicle-treated control
animals. Markers for cell cycle progression and prolifer-
ation were evaluated in the intestinal mucosa and
resveratrol decreased cyclins D1 and D2 (Schneider et al.
2001). Using 4-week-old C57BL/6J-ApcMin/C mice, Sale
et al. showed that resveratrol supplementation for 10–14
weeks in the diet (0.2% of diet; w240 mg/kg BW daily)
reduced adenoma number in the colon and small intestine
compared with control ApcMin/C mice, but a lower dose
did not significantly affect adenoma number (0.05% of
diet;w60 mg/kg BW daily) (Sale et al. 2005). After 3 weeks
on either the 0.05 or 0.2% resveratrol diet, levels of
prostaglandin E2 (PGE2) in WT male C57BL/6J mice were
reduced in the intestinal mucosa, suggesting decreased
COX2 activity (Sale et al. 2005). Using C57BL/6J-ApcMin/C
mice, however, Ziegler et al. (2004) were unable to show
that resveratrol supplementation prevented tumor forma-
tion. Specifically, the incidence of tumors or Cox2
expression was no different between male mice given
resveratrol (in diet; daily intake of 4, 20, or 90 mg/kg
starting at w6 weeks of age for 7 weeks) vs control. Sale
et al. only detected differences in adenoma load at a dose
that was much higher than either Ziegler et al. (no effect)
or Schneider et al. (positive effect). Age at which this
mouse model is treated may be critical in preventing
tumor formation; Sale et al. and Schneider et al. started
resveratrol treatment at 4 and 5 weeks of age, respectively,
while Ziegler et al. waited until 6 weeks of age to start the
supplementation. Ziegler et al., however, did find a
significant decrease in PGE2 levels in the tumors treated
with resveratrol at 90 mg/kg BW, suggesting that resver-
atrol was having some effect on Cox2 activity in the
intestinal mucosa (Ziegler et al. 2004).
Finally, resveratrol in combination with other natural
compounds may also be a viable option for the treatment
of colon cancers. In a recent study, 7-week-old female
ICR SCID mice were injected with HCT-116 (wt) cells to
initiate colon cancer formation, and 15 days post cell
injection after tumors had formed, they were treated daily
by oral gavage with both 500 mg/kg of curcumin and
150 mg/kg of resveratrol for 3 weeks (Majumdar et al.
2009). The combination of curcumin and resveratrol were
able to significantly inhibit colon cancer cell growth
compared with tumor growth in vehicle control mice, and
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this was associated with increases in apoptotic cells in the
treated mice. Both resveratrol and curcumin individually
(at the same doses as the combination) provided signi-
ficant, albeit lower levels of protection in this model as
well (Majumdar et al. 2009). Table 2 summarizes the
animal models used to investigate resveratrol and color-
ectal cancer.
Liver cancer
Liver cancer, or hepatocellular carcinoma (HCC), is one of
the most deadly forms of cancer, and its incidence has
been increasing worldwide (Llovet et al. 2003). Risk factors
for HCC include hepatitis, alcoholism, and high-fat diet
consumption (El-Serag et al. 2006, Alter 2007). Animal
models used to study the effects of resveratrol on hepatic
tumors include transplantation of liver cancer cells into
animal host and carcinogenic promotion of tumor
formation. In adult male Wistar rats injected with
AH-130 Yoshida ascites hepatoma cells, daily resveratrol
treatment (1 mg/kg BW; i.p. injection) starting at cell
implantation reduced the number of tumor cells after
7 days compared with untreated rats injected with the
hepatoma cells. Though, it is important to point out that
tumor volume was unchanged by resveratrol treatment
(Carbo et al. 1999).
Multiple studies in rats have used diethylnitrosamine
(DENA) injection followed by tumor promotion with
phenobarbital to induce HCC in the animals. In one of
these studies, Bishayee & Dhir (2009) gave resveratrol to
adult female Sprague–Dawley rats (0.06, 0.12, or 0.36%
diet; daily intake calculated to be 50, 100, or 300 mg/kg
BW) starting 4 weeks before tumor initiation and
continued for 16 weeks after initiation. Resveratrol
supplementation at 100 and 300 mg/kg BW reduced the
appearance and multiplicity of hepatocyte nodules at the
end of the study compared with DENA-treated animals
that did not receive resveratrol. Cellular architecture of the
liver tissue was also improved by resveratrol treatment at
300 mg/kg BW. In all three doses of resveratrol treatment,
there was a decrease in hepatic cellular proliferation as
indicated by reduced expression of proliferating cell
nuclear antigen (PCNA). In the livers of the two higher
doses of resveratrol-treated animals, there were also
significant increases in Bax expression and decreases in
Bcl2 expression, signifying facilitation of apoptosis by
resveratrol. Furthermore, resveratrol at higher doses
decreased lipid peroxidation and protein carbonyl content
in livers compared with control DENA-injected rats,
indicating that resveratrol might act as a free radical
scavenger and decrease the incidence of tumor formation
(Bishayee et al. 2010a). Resveratrol supplementation also
caused an increase in hepatic expression of NFE2-related
factor 2 (Nrf2 (Nfe212); Bishayee et al. 2010a). Increased
expression of Nfr2, a transcription factor involved in the
expression of antioxidant genes, suggests that resveratrol
may exert an antioxidant effect in the liver of DENA-
injected animals. Lastly, in a dose-dependent manner,
resveratrol reduced the expression of heat-shock protein
70 and COX2, as well as decreased DENA-induced
translocation of NF-kB to the nucleus, suggesting that
resveratrol is having an anti-inflammatory effect in this
model (Bishayee et al. 2010b). In a separate study, the same
group found that resveratrol reduced tumor multiplicity
in a dose-dependent manner compared with control
DENA-treated animals 14 weeks after tumor initiation. In
this study, the lowest dose of resveratrol (50 mg/kg BW)
also significantly decreased the nodule multiplicity
(Luther et al. 2011). In a more recent study, Rajasekaran
et al. (2011) have investigated the ability of resveratrol to
prevent or treat HCC in 6- to 8-week-old male Wistar rats
by treating animals daily with resveratrol (20 mg/kg BW;
oral gavage) for either 15 days starting at the DENA
injection or for 15 days after the development of HCC. In
both the early and advance stages of HCC, resveratrol
treatment increased the expression of apoptotic markers
and decreased the expression of anti-apoptotic markers.
Resveratrol treatment at both time points also reduced
cell crowding and alteration in cellular architecture as well
as decreased liver size compared with control rats
treated with DENA (Rajasekaran et al. 2011). Lin et al.
(2012) evaluated the effects of resveratrol treatment
on the precancerous stage of liver carcinogenesis in
12-month-old male hepatitis B virus X protein (HBx)
transgenic mice that spontaneously develop HCC at older
ages. Resveratrol supplementation (0.024% diet; daily
intake calculated to be 30 mg/kg BW) for 4 months
significantly reduced the incidence of HCC by 5.3-fold
and increased latency to tumor formation. The results
from liver cancer models have been consistently positive,
indicating a potential benefit for resveratrol in HCC
prevention and/or therapy.
In addition to regulation of liver cancer function,
resveratrol may also influence metastasis to the liver
from other primary cancers. Salado et al. (2011) used B16
melanoma (B16M) cells to study the effects of resveratrol
treatment on hepatic metastasis caused in large part by the
production of proinflammatory cytokines. Six- to eight-
week-old male C57BL/6J mice were given a daily oral dose
of resveratrol (1 mg/kg BW) from the day of intrasplenic
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injection of B16M cells through 12 days after injection.
Resveratrol treatments reduced hepatic metastasis volume
and metastasis number compared with vehicle control
mice given B16M cells. A summary of the methods and
findings are given in Table 3.
Pancreatic cancer
Risk for pancreatic cancer is linked to obesity, high-
fat diet, and consumption of meat products (Olsen et al.
1989, Baghurst et al. 1991). Because so many pancreatic
carcinomas are diagnosed at late, treatment-refractory
stages, prognosis for patients with pancreatic cancer is
generally poor. Clearly, there is a need for effective
treatment alternatives for pancreatic cancer. A few
researchers have looked at the in vivo effects of resveratrol
on pancreatic cancer (Table 4). Oi et al. (2010) injected
6- to 8-week old Swiss nude mice with human pancreatic
carcinoma cells (PaCa-2) to promote pancreatic tumor
xenograft formation. Resveratrol was given five times a
week by oral gavage (10 or 50 mg/kg BW) for 2 weeks
before MIA PaCa-2 injection and then continued through-
out the experiment until tumor volumes reached 1 cm3.
Resveratrol reduced tumor size and number in a dose-
dependent manner compared with animals dosed with
vehicle control. Resveratrol also inhibited the activity of
an inflammatory enzyme, leukotriene A4 hydrolase (Oi
et al. 2010). In a similar study, Harikumar et al. (2010)
injected MIA PaCa-2 cells into 4-week-old male mice and
then resveratrol was given daily (40 mg/kg BW) for a
4 week duration starting 1 week after the cells were
injected. They found that resveratrol treatment signi-
ficantly decreased tumor growth compared with
vehicle-treated mice. Combination treatment of resvera-
trol with gemcitabine further enhanced protection as well.
In 4- to 6-week old BALB/c nude mice treated five times
a week with resveratrol for 6 weeks (20, 40, or 60 mg/kg
BW by gavage) starting 1 week after tumor cell injection,
resveratrol reduced tumor growth caused by the injection
of PANC-1 cells (human pancreatic carcinoma, epithelial-
like cells) in a dose-dependent manner compared
with control mice (Roy et al. 2011). Tumor tissues from
resveratrol-treated mice also showed increased apoptosis
and decreased proliferation compared with tumor tissue
from vehicle-treated mice. This was accompanied by the
inhibition of PI3K and Akt phosphorylation leading to an
increase in the activation of the transcription factor
Forkhead box O (FOXO). Activation of FOXO results in
the expression of genes involved in cell-cycle arrest,
indicating that resveratrol reduced tumor growth through
its effects on the cell cycle (Roy et al. 2011). In 8-week-old
KrasG12D mice that spontaneously develop pancreatic
tumors, resveratrol treatment over a 10-month period for
five times a week (40 mg/kg BW by oral gavage) reduced
pancreatic lesions compared with KrasG12D that did not
receive resveratrol treatment, indicating that resveratrol
reduced spontaneous pancreatic tumors (Shankar et al.
2011). The use of all animal models of pancreatic cancer
has not shown that resveratrol supplementation is
beneficial, however. One study evaluated resveratrol
treatment (0.001% in diet) in 6-week-old male Syrian
hamsters during and after tumor initiation via
N-nitrosobis(2-oxopropyl)amine injection (Kuroiwa et al.
2006). Resveratrol did not affect the formation of
hyperplasias or adenocarcinomas in either treatment
stage. Regardless, data at this point suggest that resveratrol
either positively influences or does not significantly
impact pancreatic cancer outcomes in rodent models.
Prostate cancer
In men, prostate cancer is a leading cause of cancer-related
death in USA (Siegel et al. 2013). Diet and lifestyle may
play a major role in the development of prostate cancer
(Wolk 2005), making a supplement such as resveratrol a
promising candidate for prostate cancer chemopreven-
tion. Relatively few in vivo studies, however, have been
conducted that investigate the effects of resveratrol on
prostate cancer prevention and treatment. Two studies
have used rodent models of spontaneous prostate tumor
formation to investigate resveratrol’s protective abilities:
the transgenic adenocarcinoma of mouse prostate
(TRAMP) and the transgenic rat for adenocarcinoma of
prostate (TRAP) models (Harper et al. 2007, Seeni et al.
2008). Three additional studies have used xenograft
models to study resveratrol’s potential effects (Seeni et al.
2008, Wang et al. 2008, Dias et al. 2013).
Harper et al. (2007) administered resveratrol (0.0625%
in diet) to 5-week-old TRAMP mice daily for 23 weeks and
then observed tumor formation in the urogenital tract of
the mice. Resveratrol-fed mice had a significantly reduced
percentage of Grade 6, poorly differentiated tumors
compared with control diet-fed mice. Grade 4 lesions
were more common in resveratrol-treated mice than
control diet-fed, indicating that resveratrol slowed down
tumor progression to this stage (Harper et al. 2007). There
were, however, no differences in tumor numbers per
animal, tumor weight, latency to tumor formation, or
metastases between resveratrol treated and control
animals (Harper et al. 2007). Further, at 12 weeks of age
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after 7 weeks on the resveratrol diet, TRAMP mice showed
reduced cellular proliferation in the dorsolateral and
ventral prostate compared with control diet mice (Harper
et al. 2007).
When resveratrol was administered daily to TRAP rats
for 7 weeks (0.005, 0.01, or 0.02% in drinking water),
neoplastic lesion development was significantly reduced
in the ventral and lateral lobes of the prostate compared
with control-treated TRAP rats (Seeni et al. 2008). There
were, however, no significant differences in adenocarci-
noma incidence between resveratrol-treated and control
TRAP rats in either the ventral or lateral prostate (Seeni
et al. 2008). Protein expression of androgen receptor (AR)
was also measured in the prostate of TRAP rats; resveratrol
treatment at all three doses significantly decreased AR
expression in the ventral prostate compared with control
animals, suggesting a possible mechanism through which
resveratrol may have chemopreventative effects (Seeni
et al. 2008). Within this same paper, Seeni et al. injected rat
prostate cancer cells (PLS30 cells) into male athymic CD-1
nude mice at 6 weeks of age. Mice were then treated with
or without resveratrol (0.01 or 0.02% in drinking water)
from 1 week after the injection until they were killed at
6 weeks after the injection. Tumor volume and metastatic
foci in the lungs were measured; neither resveratrol dose
significantly affected either parameter compared with
those mice not treated with resveratrol. Seeni et al.
(2008) hypothesized that this was possibly due to the
lack of AR protein in the PLS30 cells.
Two other studies have focused on the effects of
resveratrol in human prostate cancer cells xenograft
models. In both, androgen responsive-LNCaP human
prostate cancer cells were injected s.c. into male mice
following pre-treatment with resveratrol. Wang et al.
(2008) administered resveratrol to 5-week-old BALB/
cAnNCr-nu/nu mice (0.005 or 0.01% in diet, daily) for
2 weeks before cell injection through 7 weeks after
injection. After injection, animals were palpitated for
tumor growth weekly; resveratrol at both doses in the diet
significantly delayed tumor growth by 3 weeks (both doses)
and 4 weeks (higher dose only) post injection compared
with control diet mice; however, by 7 weeks, there were no
differences in tumor volume (Wang et al. 2008). No differ-
ences in cell proliferation, measured by PCNA, were found
between the resveratrol-treated and untreated groups.
Interestingly, the resveratrol-treated animals showed signi-
ficantly lower levels of apoptosis, measured by ApopTag,
and there was increased microvessel formation (angiogen-
esis), measured by platelet/endothelial cell adhesion
molecule 1 staining, in the higher resveratrol dose mice
compared with control-fed mice (Wang et al. 2008).
Deceased apoptosis and increased angiogenesis could
lead to long-term complications and worse outcomes. A
separate study used similar tumor cells in 6- to 7-week-old
Fox n1nu mice (Dias et al. 2013). Mice were treated with
50 mg/kg of resveratrol via oral gavage every other day for
2 weeks before tumor cell injection through 5 weeks after
injection. Resveratrol significantly decreased tumor
formation and progression, as assessed by caliper measure-
ments, compared with control mice that did not receive
resveratrol. Resveratrol also caused a decrease in serum
interleukin 6 (IL6; Dias et al. 2013). As part of the same
experiment, Dias et al. (2013) also studied the effects
of two resveratrol analogs that could have better bio-
availability (trimethoxy-resveratrol and piceatannol) and
found that both decreased tumor volume and IL6 in
mouse serum. These compounds should be tested in
additional studies. Data from these models suggest that
resveratrol may have some positive impacts on prostate
tumor formation and progression, but it may have some
unwanted effects on angiogenesis around the tumors.
Additional work needs to be done in this area. A summary
of the prostate cancer studies is provided in Table 5.
Discussion
Although there is some in vivo evidence for the use of
resveratrol as a chemopreventative agent, there is still
much more research that needs to be done on tumor
induction methods and dose selection as well as age- and
sex-specific effects of resveratrol supplementation. Tables
1, 2, 3, 4 and 5 highlight the differences in the in vivo
models used, including cancer models, methods of tumor
initiation, strain, species, sex, method/timing of resvera-
trol administration, and dose of resveratrol. The tables
show that there is no consistent technique used for
resveratrol administration. Resveratrol delivery (large
single daily dose by oral gavage or injection vs small
doses throughout the day/night when resveratrol is
provided in food or drinking water) could have critical
effects on cancer outcomes due to the quick absorption
and metabolism of resveratrol. Furthermore, many papers
did not measure or report circulating resveratrol levels
which makes comparison across strains, species, and
studies nearly impossible. The source (purified from
Japanese knotweed, chemically synthesized, etc.) and
purity of resveratrol were not reported in all papers and
could also play a role in inconsistent effects observed in
the studies. It is also important to take into account the
fact that doses in animals generally cannot be directly
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translated to humans, for example, it may be important to
normalize dosing to body surface area as opposed to BW
(Reagan-Shaw et al. 2008).
There is little evidence from animal or human studies
that resveratrol can serve as a viable treatment option once
tumors are already formed, so it is not likely that
resveratrol can be used as an alternative for the traditional
forms of cancer treatment in the near future. Further,
resveratrol supplementation had no effect on spontaneous
neoplasia formation in WT C57BL/6 male mice fed
resveratrol in their diet (0.01 or 0.04%) from 12 months
of age through the remainder of their lives (Pearson et al.
2008). Also, resveratrol does not appear to target the
cellular structures involved in proliferation such as
microtubules or nucleotide synthetic enzymes that many
of the traditional chemotherapeutics target; therefore
resveratrol is unlikely to be efficacious as a primary anti-
cancer agent. Rather, resveratrol appears to maintain
cellular homeostasis in part by protecting cells against
oxidative injury and other cancer-causing perturbations.
The addition of resveratrol to standard chemotherapeutic
regimens may therefore be helpful in preventing the
development of secondary malignancies that result from
mutagenic effects of chemotherapy and radiotherapy
(Kinghorn et al. 2004, Aziz et al. 2005, Le Corre et al.
2005, Lee & Lee 2006, Khan et al. 2008, Kundu & Surh
2008, Dennis et al. 2009, Seehusen et al. 2010, Newhauser
& Durante 2011, Szekeres et al. 2011). Resveratrol may also
help to prevent other long-term morbidities associated
with anti-cancer therapy, such as cardiac myocyte toxicity
and subsequent heart failure from exposure to anthra-
cyclines such as doxorubicin (Tatlidede et al. 2009). Thus,
although resveratrol is not likely to be a primary treatment
for cancer, in addition to its potential role in primary
cancer prevention by reducing carcinogenesis for primary
malignancies, it may have a role in the prevention of
secondary malignancies and/or other toxic effects of
traditional chemotherapeutic agents. As a result, it is
important to emphasize further resveratrol supple-
mentation as a way to prevent the development of cancer
and disease and as a supplement used in conjugation with
traditional chemotherapeutics.
After oral administration, trans-resveratrol is quickly
conjugated into glucuronides and sulfates (Andlauer et al.
2000, De Santi et al. 2000, Soleas et al. 2001, Yu et al. 2002).
Because the bioavailability of trans-resveratrol after oral
administration is low (Wenzel & Somoza 2005), research-
ers have recently started to investigate the effects
of resveratrol derivatives with higher bioavailability
(Szekeres et al. 2011, Dias et al. 2013). Also, some of the
efforts to improve resveratrol’s bioavailability have
focused on combination therapy with other compounds
that may prevent or delay conjugation of resveratrol.
Piperine, a compound found in black pepper, can inhibit
glucuronidation (Reen et al. 1993, Shoba et al. 1998). In
mice, piperine significantly increased the serum levels of
resveratrol after oral administration of both compounds
(Johnson et al. 2011). Other studies have focused on the
synergistic effects of resveratrol and other naturally
occurring compounds such as melatonin, tea polyphe-
nols, and quercetin on cancer models; for a thorough
review of these studies see Singh et al. (2013).
Epidemiological studies have found strong corre-
lations between obesity and certain types of cancers
including breast, endometrial, colorectal, pancreatic, and
HCCs (Moller et al. 1994, Galanis et al. 1998, Silverman
et al. 1998, Gapstur et al. 2000, Trentham-Dietz et al. 2000,
Vainio et al. 2002, Calle et al. 2003). Excessive amounts of
body fat can cause changes in hormone and protein levels
that result in cellular deregulation, and therefore possibly
cancer. Therefore, targeting obesity may be a way to
prevent and/or lower risk of cancer development. Resver-
atrol is an important molecule to consider in this area of
cancer prevention since it has been shown to have many
positive effects on animal models of obesity and high-fat
diet. In animal studies, resveratrol was found to prolong
survival and decrease fat mass in mice fed a high-fat diet
(Baur et al. 2006, Lagouge et al. 2006). Resveratrol
treatment also decreased hyperglycemia in a model of
diet-induced diabetes as well as improved insulin sensi-
tivity when insulin resistance has developed due to
increased fat mass (Ramadori et al. 2009, Kang et al.
2012). In some initial clinical trials, resveratrol supple-
mentation improved glucose regulation in aged subjects
with impaired glucose tolerance and improved homeo-
static model assessment index in obese men (Timmers
et al. 2011, Crandall et al. 2012). Also, in two separate
studies looking at resveratrol supplementation in type 2
diabetics, resveratrol improved insulin sensitivity and
HbA1c measurements (Brasnyo et al. 2011, Bhatt et al.
2012). Other groups were unable to show improvements
in insulin sensitivity or glucose regulation with resveratrol
treatment. In both normal weight and obese subjects,
resveratrol use was unable to improve insulin sensitivity
and glucose uptake into tissues when measured by
hyperinsulinemic–euglycemic clamp (Yoshino et al.
2012, Poulsen et al. 2013). Similar to the animal studies
looking at resveratrol and cancer, differences in the
amount and length of resveratrol treatment could be a
factor in differences observed between studies. However,
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there is some promising evidence that resveratrol can
improve metabolic outcomes and could have a major
impact on overall health, including decreasing cancer risk.
Conclusion
Research has shown that resveratrol supplementation
could potentially have many positive health benefits
including decreased cancer risk. Yet, there are limited
clinical trials with small sample sizes, and animal models
have had mixed results. There is a need for more extensive
and consistent studies in animal models. Little evidence
exists that resveratrol can be used effectively to treat
preexisting tumors (that were not implanted cells); there-
fore the most promising use of resveratrol is most likely as
a cancer preventative agent. Determining the efficacy and
appropriateness for resveratrol as a cancer preventive or
anti-cancer agent is likely to be an area of emphasis for
future research studies and clinical trials. Resveratrol may
impact certain tumor types more so than others, based on
its proposed mechanisms of action and different onco-
genic pathways being tumor-specific. In addition, much
work needs to be done on optimizing the bioavailability
of the drug and determining its pharmacokinetic,
pharmacodynamics, and safety profile in different patient
populations (e.g. adults vs pregnant women vs children).
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